Suppr超能文献

生物标志物:实现分子驱动、定量健康的期望。

Biomarkers: Delivering on the expectation of molecularly driven, quantitative health.

机构信息

1 171702 Bioengineering Department, Stanford University , Stanford, CA 94305, USA.

2 Department of Genetics, Stanford University, Stanford, CA 94305, USA.

出版信息

Exp Biol Med (Maywood). 2018 Feb;243(3):313-322. doi: 10.1177/1535370217744775. Epub 2017 Dec 3.

Abstract

Biomarkers are the pillars of precision medicine and are delivering on expectations of molecular, quantitative health. These features have made clinical decisions more precise and personalized, but require a high bar for validation. Biomarkers have improved health outcomes in a few areas such as cancer, pharmacogenetics, and safety. Burgeoning big data research infrastructure, the internet of things, and increased patient participation will accelerate discovery in the many areas that have not yet realized the full potential of biomarkers for precision health. Here we review themes of biomarker discovery, current implementations of biomarkers for precision health, and future opportunities and challenges for biomarker discovery. Impact statement Precision medicine evolved because of the understanding that human disease is molecularly driven and is highly variable across patients. This understanding has made biomarkers, a diverse class of biological measurements, more relevant for disease diagnosis, monitoring, and selection of treatment strategy. Biomarkers' impact on precision medicine can be seen in cancer, pharmacogenomics, and safety. The successes in these cases suggest many more applications for biomarkers and a greater impact for precision medicine across the spectrum of human disease. The authors assess the status of biomarker-guided medical practice by analyzing themes for biomarker discovery, reviewing the impact of these markers in the clinic, and highlight future and ongoing challenges for biomarker discovery. This work is timely and relevant, as the molecular, quantitative approach of precision medicine is spreading to many disease indications.

摘要

生物标志物是精准医学的基石,正在实现分子水平、量化健康的预期。这些特性使临床决策更加精确和个性化,但需要高标准的验证。生物标志物在癌症、药物遗传学和安全性等一些领域改善了健康结果。蓬勃发展的大数据研究基础设施、物联网和增加的患者参与度将加速在许多尚未充分发挥生物标志物在精准健康方面潜力的领域的发现。在这里,我们回顾了生物标志物发现的主题、目前用于精准健康的生物标志物的实施情况,以及生物标志物发现的未来机遇和挑战。影响声明精准医学的发展是因为人们认识到人类疾病是由分子驱动的,并且在患者之间存在高度的可变性。这种认识使生物标志物(一类多样化的生物学测量)在疾病诊断、监测和治疗策略选择方面更加相关。生物标志物对精准医学的影响可以在癌症、药物基因组学和安全性方面看到。这些案例的成功表明,生物标志物在更广泛的人类疾病谱中具有更多的应用和更大的精准医学影响力。作者通过分析生物标志物发现的主题、回顾这些标志物在临床中的影响,以及强调生物标志物发现的未来和正在进行的挑战,来评估基于生物标志物的医疗实践的现状。这项工作具有及时性和相关性,因为精准医学的分子、定量方法正在传播到许多疾病适应症。

相似文献

3
Pharmacogenomics: Driving Personalized Medicine.药物基因组学:推动个性化医疗。
Pharmacol Rev. 2023 Jul;75(4):789-814. doi: 10.1124/pharmrev.122.000810. Epub 2023 Mar 16.
7
Artificial intelligence in early drug discovery enabling precision medicine.人工智能在早期药物发现中实现精准医学。
Expert Opin Drug Discov. 2021 Sep;16(9):991-1007. doi: 10.1080/17460441.2021.1918096. Epub 2021 Jun 2.

引用本文的文献

2
Prognostic Value of miR-10a-3p in Non-Small Cell Lung Cancer Patients.miR-10a-3p在非小细胞肺癌患者中的预后价值
Onco Targets Ther. 2024 Nov 14;17:1017-1032. doi: 10.2147/OTT.S475644. eCollection 2024.
8
A scientist engineer's contribution to therapeutic discovery and development.一位科学家工程师对治疗方法发现与开发的贡献。
Exp Biol Med (Maywood). 2018 Oct;243(14):1125-1132. doi: 10.1177/1535370218813974. Epub 2018 Nov 20.

本文引用的文献

2
Biomarkers of response to PD-1/PD-L1 inhibition.PD-1/PD-L1抑制反应的生物标志物。
Crit Rev Oncol Hematol. 2017 Aug;116:116-124. doi: 10.1016/j.critrevonc.2017.06.001. Epub 2017 Jun 9.
6
Disease Biomarkers for Precision Medicine: Challenges and Future Opportunities.精准医学的疾病生物标志物:挑战与未来机遇
Genomics Proteomics Bioinformatics. 2017 Apr;15(2):57-58. doi: 10.1016/j.gpb.2017.04.001. Epub 2017 Apr 7.
10
Synthetic lethality: emerging targets and opportunities in melanoma.合成致死性:黑色素瘤中的新兴靶点与机遇
Pigment Cell Melanoma Res. 2017 Mar;30(2):183-193. doi: 10.1111/pcmr.12573. Epub 2017 Mar 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验